EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population‐based competing risk analysis

Jeffrey Shi Kai Chan iD, Yan Hiu Athena Lee, Jeremy Man Ho Hui, Kang Liu, Edward Christopher Dee, Kenrick Ng, Tong Liu iD, Gary Tse, Chi Fai Ng

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Jeffrey Shi Kai Chan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong - China - UK Collaboration, Hong Kong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Hong Kong Metropolitan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our study investigated how adverse cardiovascular outcomes are impacted by cardiovascular comorbidities in patients with prostate cancer treated by androgen deprivation therapy (ADT). Using prospective, population‐based data, all Hong Kong patients with prostate cancer who received ADT during 1 January 1993 to 3 March 2021 were identified and followed up for the endpoint of cardiovascular hospitalization/mortality until 31 September 2021, whichever earlier. Multivariable competing risk regression was used to compare the endpoint's cumulative incidence between different combinations of major cardiovascular comorbidities (heart failure [HF], myocardial infarction [MI], stroke and/or arrhythmia), with noncardiovascular death as competing event. Altogether, 13 537 patients were included (median age 75.9 [interquartile range 70.0‐81.5] years old; median follow‐up 3.3 [1.5‐6.7] years). Compared to those with none of prior HF/MI/stroke/arrhythmia, the incidence of the endpoint was not different in those with only stroke (subhazard ratio [SHR] 1.06 [95% confidence interval (CI): 0.92‐1.23], P = .391), but was higher in those with only HF (SHR 1.67 [1.37‐2.02], P < .001), arrhythmia (SHR 1.63 [1.35‐1.98], P < .001) or MI (SHR 1.43 [1.14‐1.79], P = .002). Those with ≥2 of HF/MI/stroke/arrhythmia had the highest incidence of the endpoint (SHR 1.94 [1.62‐2.33], P < .001), among whom different major cardiovascular comorbidities had similar prognostic impacts, with the number of comorbidities present being significantly prognostic instead. In conclusion, in patients with prostate cancer receiving ADT, the sole presence of HF, MI or arrhythmia, but not stroke, may be associated with elevated cardiovascular risks. In those with ≥2 of HF/MI/stroke/arrhythmia, the number of major cardiovascular comorbidities may be prognostically more important than the type of comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansAgedAged, 80 and overAndrogen AntagonistsAndrogensPrognosisProspective StudiesRisk FactorsRisk Assessment

Stichwörter der Autor:innen

androgen deprivation therapycardio-oncologycomorbidityhospitalizationmortalityprostate cancer

Substanzen

Androgen AntagonistsAndrogens

Autor:innen und Institutionen

  • Cardio-Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong - China - UK Collaboration, Hong Kong, China.
  • Division of Urology, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
  • Kent and Medway Medical School, Canterbury, UK.

ORCID-Profile: Jeffrey Shi Kai Chan, Tong Liu

Förderung

  • NCI NIH HHS
  • Hong Kong Metropolitan University

Zitieren

APA

Chan, J. S. K., Lee, Y. H. A., Hui, J. M. H., Liu, K., Dee, E. C., Ng, K., Liu, T., Tse, G., & Ng, C. F. (2023). Long‐term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population‐based competing risk analysis. International Journal of Cancer. https://doi.org/10.1002/ijc.34557

Vancouver

Chan JSK, Lee YHA, Hui JMH, Liu K, Dee EC, Ng K, et al. Long‐term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population‐based competing risk analysis. International Journal of Cancer. 2023. doi:10.1002/ijc.34557

BibTeX
@article{Chan2023,
  author = {Chan, Jeffrey Shi Kai and Lee, Yan Hiu Athena and Hui, Jeremy Man Ho and Liu, Kang and Dee, Edward Christopher and Ng, Kenrick and Liu, Tong and Tse, Gary and Ng, Chi Fai},
  title = {Long‐term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population‐based competing risk analysis},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34557}
}
Kostenlos starten →